P
ProMIS Neurosciences D
D
PMN
8.32000
USD
-0.11
(-1.30%)
Market Closed
Last updated: · Delayed 15 min
Volume
334
EPS
-7
Div Yield
-
P/E
-1
Market Cap
74,611,206
Title: Promis Neurosciences Inc.
Sector: Healthcare
Industry: Biotechnology
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.